Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 84,34 € (-3,49 %). La mediana es de 89,33 € (+2,22 %).
| Comprar |
11 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline
Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Más en de.investing.com
Kiniksa Pharmaceuticals reaches record high at $64.85
Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Más en de.investing.com
Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%
Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Más en de.investing.com
Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance
Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Más en de.investing.com
Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket
Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 252,47 M | 63,82 % |
| Beneficio bruto | 134,53 M | 62,32 % |
| Beneficio neto | 41,8 M | 166,08 % |
| EBITDA | 52,57 M | 124,01 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 6863,85 M € |
Número de acciones | 78,57 M |
Máximo/mínimo de 52 semanas | 90,06 € - 33,57 € |
| Dividendos | No |
Beta | 0,08 |
Ratio P/E | 67,36 |
Ratio PEG | 0,35 |
Ratio P/B | 10,61 |
Ratio P/S | 8,00 |
Perfil de la empresa
Kiniksa Pharmaceuticals, Ltd., una empresa biofarmacéutica, se centra en descubrir, adquirir, desarrollar y comercializar medicamentos terapéuticos para pacientes que padecen enfermedades debilitantes con necesidades médicas no cubiertas significativas en todo el mundo. Sus candidatos a producto incluyen ARCALYST, un inhibidor de la interleucina-1alfa y la interleucina-1beta, para el tratamiento de la pericarditis recurrente, una enfermedad cardiovascular inflamatoria; Mavrilimumab, un anticuerpo monoclonal inhibidor que completó ensayos clínicos de fase II para el tratamiento de la arteritis de células gigantes; Vixarelimab, un anticuerpo monoclonal, que se encuentra en un ensayo clínico de fase 2a para el tratamiento del prurigo nodular, una afección cutánea inflamatoria crónica; y KPL-404, un anticuerpo monoclonal inhibidor de la interacción CD40-CD154, una señal coestimuladora de los linfocitos T fundamental para la maduración de los linfocitos B, el cambio de clase de inmunoglobulinas y la respuesta inmunitaria de tipo 1. Kiniksa Pharmaceuticals, Ltd. se constituyó en 2015 y tiene su sede en Hamilton, Bermudas.
| Nombre | KINIKSA A BE-,000273235 |
| CEO | Sanj K. Patel |
| Sede | London,
gl Bermudas |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 25/05/2018 |
| Empleados | 366 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | KNSA |